Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).
Aguado de la Rosa C, Cruz Castellanos P, Lázaro-Quintela M, Dómine M, Vázquez Estévez S, López-Vivanco G, Fírvida Pérez JL, Alonso Romero JL, Ferrera Delgado L, García Girón C, Diz Taín P, Álvarez Álvarez R, Mut Sanchís P, Fernández Cantón I, Manrique Abós I, Martínez Aguillo M, Gómez-Aldaraví Gutiérrez L, Ortega Granados AL, Álvarez Cabellos R, García Sebastián A, García Sifuentes LF, Reguart N.
Aguado de la Rosa C, et al. Among authors: alvarez alvarez r.
Lung Cancer. 2022 Nov;173:83-93. doi: 10.1016/j.lungcan.2022.09.010. Epub 2022 Sep 19.
Lung Cancer. 2022.
PMID: 36162227
Free article.